BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34129844)

  • 1. YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.
    Lu X; Peng B; Chen G; Pes MG; Ribback S; Ament C; Xu H; Pal R; Rodrigues PM; Banales JM; Evert M; Calvisi DF; Chen X; Fan B; Wang J
    Am J Pathol; 2021 Sep; 191(9):1651-1667. PubMed ID: 34129844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
    Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
    Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
    Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
    J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
    Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
    Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    Song X; Xu H; Wang P; Wang J; Affo S; Wang H; Xu M; Liang B; Che L; Qiu W; Schwabe RF; Chang TT; Vogl M; Pes GM; Ribback S; Evert M; Chen X; Calvisi DF
    J Hepatol; 2021 Oct; 75(4):888-899. PubMed ID: 34052254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
    Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
    BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration.
    Liu C; Cheng X; Chen J; Wang Y; Wu X; Tian R; Liu B; Ding X; Sun Q; Gong W
    Theranostics; 2019; 9(13):3840-3852. PubMed ID: 31281517
    [No Abstract]   [Full Text] [Related]  

  • 11. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
    Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
    Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
    Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
    Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
    Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
    Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling.
    Shu Y; Xu Q; Xu Y; Tao Q; Shao M; Cao X; Chen Y; Wu Z; Chen M; Zhou Y; Zhou P; Shi Y; Bu H
    Cell Death Dis; 2021 Oct; 12(11):966. PubMed ID: 34667161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
    Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T
    Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous activation of Kras-Akt and Notch pathways induces extrahepatic biliary cancer via the mTORC1 pathway.
    Namikawa M; Fukuda A; Mizukoshi K; Iwane K; Kawai M; Yamakawa G; Omatsu M; Sono M; Masuda T; Araki O; Nagao M; Yoshikawa T; Ogawa S; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Tsuruyama T; Taura K; Hatano E; Seno H
    J Pathol; 2023 Aug; 260(4):478-492. PubMed ID: 37310065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.